Epidermal growth factor receptor tyrosine kinase inhibitor in treatment of elderly patients with nonsmall-cell lung cancer
10.3760/cma.j.issn.1671-7368.2012.03.028
- VernacularTitle:表皮生长因子受体酪氨酸激酶抑制剂治疗老年晚期非小细胞肺癌临床分析
- Author:
Jingying NONG
;
Jinghui WANG
;
Xinjie YANG
;
Yifen SUN
;
Xinyong ZHANG
;
Yuhua WU
;
Xi LI
;
Hui ZHANG
;
Na QIN
;
Quan ZHANG
;
Shucai ZHANG
- Publication Type:Journal Article
- Keywords:
Carcinoma non-small-cell lung;
Receptor,epidermal growth factor
- From:
Chinese Journal of General Practitioners
2012;11(3):221-223
- CountryChina
- Language:Chinese
-
Abstract:
Seventy patients with advanced non-small-cell lung cancer (NSCLC) aged 65 or above were treated with epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) erlotinib or gefitinib from February 2006 to September 2010. The efficacy and toxicities of treatment were retrospectively analyzed.The overall response rate and disease control rate were 31.4％ and 84.3％,respectively. Themedian progression-free survival time and median survival time were 8.0 months and 13.5 months,respectively(P ＜ 0.05 ). One-year survival rate was 54.3％. Response rate ( CR + PR) ( 42.9％ ) anddisease control rate (94.3％ )in female patients were superior to males (20.0％ and 74.3％ ) (P ＜ 0.05 ).Non-smoking and PS score ＜ 2 were good predictors for survival.The side effects were generally mild and mainly were skin rash and diarrhea.
